Related Experiment Video
Updated: Jun 21, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
Published on: May 11, 2022
C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.
Yorrick R J Jaspers1, Inge M E Dijkstra1, Marc Engelen2
1Laboratory Genetic Metabolic Diseases, Department of Laboratory Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam Neuroscience, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands.
X-linked adrenoleukodystrophy (ALD) is diagnosed using C26:0-lysophosphatidylcholine (LPC(26:0)), a marker that also predicts disease severity and aids in monitoring treatment effectiveness. This biomarker offers improved accuracy over traditional methods.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- X-linked adrenoleukodystrophy (ALD) is a progressive neurometabolic disorder.
- Pathogenic variants in the ABCD1 gene lead to very-long-chain fatty acids (VLCFAs) accumulation.
- C26:0-lysophosphatidylcholine (LPC(26:0)) is the primary biomarker for ALD.
Purpose of the Study:
- To evaluate LPC(26:0) as a superior diagnostic and prognostic biomarker for ALD.
- To explore the role of LPC(26:0) in ALD pathogenesis and therapeutic monitoring.
Main Methods:
- LC-MS/MS and FIA-MS/MS analysis of LPC(26:0) in plasma and dried blood spots.
- Comparison with conventional plasma VLCFA analysis.
- Correlation analysis of LPC(26:0) levels with disease severity and clinical outcomes.
Main Results:
- LPC(26:0) measurement shows higher sensitivity and specificity than VLCFA analysis, particularly in female patients.
- Elevated LPC(26:0) levels correlate with cerebral ALD, adrenal insufficiency, and spinal cord disease.
- Neonatal LPC(26:0) levels may predict early-onset disease.
- LPC(26:0) exhibits neurotoxic and proinflammatory properties in experimental models.
- LPC(26:0) serves as a pharmacodynamic biomarker for therapeutic interventions.
Conclusions:
- LPC(26:0) is a highly sensitive and specific biomarker for ALD diagnosis and risk stratification.
- LPC(26:0) is implicated in ALD pathogenesis and can monitor treatment response.
- Further research is needed to determine the origin and precise role of LPC(26:0) in neuroinflammation and clinical outcome prediction.
Related Concept Videos
Lysosomal Hydrolases
Sex-linked Disorders
Synthesis of Phosphatidylcholine in the ER Membrane
The major components of all eukaryotic cell...

